Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Syndax Pharmaceuticals, Inc. - Common Stock (NQ:SNDX)

20.96 +0.08 (+0.38%)
Streaming Delayed Price Updated: 3:11 PM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Syndax Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Vail Resorts, Carnival, Opera And Other Big Stocks Moving Lower On Friday ↗
U.S. stocks traded higher, with the Nasdaq Composite gaining around 1% on Friday. Here are some big stocks recording losses in today’s session. Corcept Therapeutics Incorporated (NASDAQ: CORT) shares... 
Via Benzinga
Topics Stocks
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  During the session on Thursday, 461 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Earnings Scheduled For August 3, 2023 ↗
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  Friday's session saw 169 companies set new 52-week lows. 
Via Benzinga
News headline image
Citigroup Maintains Buy Rating for Syndax Pharmaceuticals: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
What 7 Analyst Ratings Have To Say About Syndax Pharmaceuticals ↗
 
Via Benzinga
News headline image
Syndax Pharmaceuticals Earnings Preview ↗
 
Via Benzinga
News headline image
Expert Ratings for Syndax Pharmaceuticals ↗
 
Via Benzinga
News headline image
Syndax Pharmaceuticals's Earnings: A Preview ↗
 
Via Benzinga
News headline image
Analyst Expectations for Syndax Pharmaceuticals's Future ↗
 
Via Benzinga
News headline image
Syndax Highlights Durable Remissions For Revumenib In Acute Leukemia Patients ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  Monday's session saw 175 companies set new 52-week lows. 
Via Benzinga
News headline image
Syndax-Incyte Partnered Chronic Graft-Versus-Host Disease Achieves Primary Endpoint In Pivotal Trial, FDA Submission Planned By 2023 End ↗
Syndax Pharmaceuticals (NASDAQ: SNDX) and Incyte Corporation (NASDAQ: INCY) announced topline data from the AGAVE-201 trial of axatilimab, in adult and pediatric patients with chronic graft-versus-host... 
Via Benzinga
News headline image
Syndax Pharmaceuticals Set for Potential Breakthrough with Revumenib: Analyst Calls It 'Potentially Best-In-Class' In Competitive Landscape ↗
Guggenheim Partners initiated coverage on Syndax Pharmaceuticals Inc (NASDAQ: SNDX) with a BUY rating and a  
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 8, 2023 ↗
Companies Reporting Before The Bell • HNI (NYSE:HNI) is likely to report quarterly loss at $0.03 per share on revenue of $462.26 million. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2023 ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 28, 2023 ↗
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter. 
Via Benzinga
News headline image
United Natural Foods, Ollie's Bargain, Smith & Wesson Brands And Some Other Big Stocks Moving Lower On Wednesday ↗
U.S. stocks traded mostly lower, with the Nasdaq Composite dropping over 60 points on Wednesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
Earnings Preview For Syndax Pharmaceuticals ↗
Syndax Pharmaceuticals (NASDAQ:SNDX) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
News headline image
Stock Market Rally Rises On Inflation Data; Nvidia, Micron, Tesla, Disney In Focus: Weekly Review ↗
The major indexes continued to advance, despite some key warnings. 
Via Investor's Business Daily
News headline image
Earnings Scheduled For November 3, 2022 ↗
Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion. 
Via Benzinga
News headline image
Amphastar, Syndax Top Second-Quarter Estimates, But Runaway Biotechs At A Standstill ↗
Amphastar came in well above forecasts, while Syndax had fewer than expected losses. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Gainers 
Via Benzinga
News headline image
Syndax Pharmaceuticals Stock Sees RS Rating Rise To 92 ↗
Syndax Pharmaceuticals stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 80 to 92. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Gainers Ocular Therapeutix (NASDAQ:OCUL) shares moved upwards by 12.3% to $4.01 during Friday's after-market session. The company's market cap stands at $307.7 million. 
Via Benzinga
News headline image
Earnings Scheduled For August 8, 2022 ↗
Companies Reporting Before The Bell • Pyxis Tankers (NASDAQ:PXS) is likely to report earnings for its second quarter. 
Via Benzinga
News headline image
Earnings Scheduled For May 9, 2022 ↗
Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 11, 2022 ↗
Upgrades 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.